Cargando…

Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)

The negative symptoms of schizophrenia are an unmet treatment target as currently approved treatments mostly control positive symptoms. The persistence of these symptoms holds back the patient's reinstatement in society, making them incapable of fulfilling their social, professional, or family...

Descripción completa

Detalles Bibliográficos
Autores principales: Căpățînă, Octavia O., Micluția, Ioana V., Fadgyas-Stănculete, Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851661/
https://www.ncbi.nlm.nih.gov/pubmed/33603883
http://dx.doi.org/10.3892/etm.2021.9707
_version_ 1783645673862725632
author Căpățînă, Octavia O.
Micluția, Ioana V.
Fadgyas-Stănculete, Mihaela
author_facet Căpățînă, Octavia O.
Micluția, Ioana V.
Fadgyas-Stănculete, Mihaela
author_sort Căpățînă, Octavia O.
collection PubMed
description The negative symptoms of schizophrenia are an unmet treatment target as currently approved treatments mostly control positive symptoms. The persistence of these symptoms holds back the patient's reinstatement in society, making them incapable of fulfilling their social, professional, or family roles. There is overwhelming research evidence suggesting that the negative symptoms of schizophrenia are associated with poorer functioning and lower quality of life than positive symptoms, confirming the need for developing new treatments for this particular category of symptoms. This present review aims to review clinical trials addressing novel pharmacological approaches addressing primary negative symptoms of schizophrenia. We overview both monotherapies, first-generation and second-generation antipsychotics, and add-on therapies, including psychostimulants, anti-inflammatory drugs, antidepressants, molecules targeting glutamatergic, cholinergic or serotonergic systems and hormones. Our findings suggest that the primary negative symptoms of schizophrenia may be mitigated by adjunctive therapies, and we highlight the pharmacological agents that have proven superior efficacy. Novel compounds such as cariprazine and MIN-101, to date, show promising results, but large clinical trials are needed to test their efficacy and safety.
format Online
Article
Text
id pubmed-7851661
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-78516612021-02-17 Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review) Căpățînă, Octavia O. Micluția, Ioana V. Fadgyas-Stănculete, Mihaela Exp Ther Med Review The negative symptoms of schizophrenia are an unmet treatment target as currently approved treatments mostly control positive symptoms. The persistence of these symptoms holds back the patient's reinstatement in society, making them incapable of fulfilling their social, professional, or family roles. There is overwhelming research evidence suggesting that the negative symptoms of schizophrenia are associated with poorer functioning and lower quality of life than positive symptoms, confirming the need for developing new treatments for this particular category of symptoms. This present review aims to review clinical trials addressing novel pharmacological approaches addressing primary negative symptoms of schizophrenia. We overview both monotherapies, first-generation and second-generation antipsychotics, and add-on therapies, including psychostimulants, anti-inflammatory drugs, antidepressants, molecules targeting glutamatergic, cholinergic or serotonergic systems and hormones. Our findings suggest that the primary negative symptoms of schizophrenia may be mitigated by adjunctive therapies, and we highlight the pharmacological agents that have proven superior efficacy. Novel compounds such as cariprazine and MIN-101, to date, show promising results, but large clinical trials are needed to test their efficacy and safety. D.A. Spandidos 2021-03 2021-01-25 /pmc/articles/PMC7851661/ /pubmed/33603883 http://dx.doi.org/10.3892/etm.2021.9707 Text en Copyright: © Căpățînă et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Căpățînă, Octavia O.
Micluția, Ioana V.
Fadgyas-Stănculete, Mihaela
Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
title Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
title_full Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
title_fullStr Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
title_full_unstemmed Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
title_short Current perspectives in treating negative symptoms of schizophrenia: A narrative review (Review)
title_sort current perspectives in treating negative symptoms of schizophrenia: a narrative review (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851661/
https://www.ncbi.nlm.nih.gov/pubmed/33603883
http://dx.doi.org/10.3892/etm.2021.9707
work_keys_str_mv AT capatinaoctaviao currentperspectivesintreatingnegativesymptomsofschizophreniaanarrativereviewreview
AT miclutiaioanav currentperspectivesintreatingnegativesymptomsofschizophreniaanarrativereviewreview
AT fadgyasstanculetemihaela currentperspectivesintreatingnegativesymptomsofschizophreniaanarrativereviewreview